NVO Deadline: NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Novo Nordisk A/S securities between November 2, 2022, and December 19, 2024, of the March 25, 2025, lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Novo Nordisk securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by March 25, 2025 [2]. - The lawsuit claims that during the Class Period, defendants made misleading statements regarding the phase 3 CagriSema study on obesity, particularly about the expected outcomes and the nature of the trial protocol [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [3]. - The firm has been recognized for its achievements, including the largest securities class action settlement against a Chinese company at the time and being ranked highly for the number of settlements [3]. Group 3: Case Specifics - The lawsuit alleges that defendants provided overly positive statements about the CagriSema study, including an expected minimum average weight loss of 25% for patients, while concealing material adverse facts about the trial's flexible dosing protocol [4].